Thomas K Karikari

Thomas K Karikari, PhD

Assistant Professor

Department of Psychiatry

School of Medicine

University of Pittsburgh, USA

About the Speaker:

Education & Training

PhD   Neuroscience, University of Warwick

Postdoctoral   Neuroscience, University of Gothenburg

Professional Affiliations

Committee for Aid in Education in Neurochemistry, International Society for Neurochemistry

Selected Honors & Awards

Best Alzheimer publication Award, Swedish Alzheimer Foundation

Astrup Prize, Nordic Federation for Clinical Chemistry

Research Interests

Pathological changes in the Alzheimer brain; Blood biomarkers for Alzheimers disease diagnosis

Selected Recent Publications:

1. Islam T, Hill E, Abrahamson EE, Servaes S, Smirnov DS, Zeng X, Sehrawat A, Chen Y, Kac PR, Kvartsberg H, Olsson M, Sjons E, Gonzalez-Ortiz F, Therriault J, Tissot C, Del Popolo I, Rahmouni N, Richardson A, Mitchell V, Zetterberg H, Pascoal TA et al. (2025) Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease. Nat Med. 2025 Feb 10. Online ahead of print.

2. Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, Karikari TK, Apostolova L, Murray ME, Verberk I, Vogel JW, La Joie R, Gauthier S, Teunissen C, Rabinovici GD, Zetterberg H, Bateman RJ, Scheltens P, Blennow K, Sperling R et al. (2024) Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat Rev Neurol 20:232-244.

3. Balusu S, Horré K, Thrupp N, Craessaerts K, Snellinx A, Serneels L, T'Syen D, Chrysidou I, Arranz AM, Sierksma A, Simrén J, Karikari TK, Zetterberg H, Chen WT, Thal DR, Salta E, Fiers M, De Strooper B (2023) MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer's disease. Science 381:1176-1182.

4. Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD, Suárez-Calvet M et al. (2022) Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nat Med 28:1797-1801.

5. Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, González-Ortiz F, Di Molfetta G, Meda FJ, Jonaitis EM, Koscik RL, Cody K, Betthauser TJ, Li Y, Vanmechelen E, Palmqvist S, Stomrud E, Bateman RJ, Zetterberg H et al. (2022) Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring. Nat Med 28:2555-2562.